MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'epithelial'. Sat, 03 Sep 2011 02:58:40 +0100 http://www.medworm.com/index.php?rid=4549944&cid=t_127014_155_f&fid=38412&url=http%3A%2F%2Fpathlabmed.typepad.com%2Fsurgical_pathology_and_la%2F2011%2F03%2Fevidence-for-tissue-specific-differences-in-emt.html Remodeling of the extracellular matrix is a key process in cancer invasion.  Matrix metalloproteases (MMPs) have been shown to be important in ECM remodeling but identifying individual MMPs with specific roles in various cancers has been difficult due to functional overlap with other proteases.  The current Diseases Models and Mechanisms has an interesting article by Hald et al. in which they demonstrate that double-knockout mice lacking both plasmin and MMP-9 develop inflammatory colonic mass lesions that resemble mucosal prolapse lesions in humans.  In contrast, wound healing in skin in these mice is normal.  The findings indicate tissue-specific differences in ECM remodeling--and thus potential therapeutic targets. Further, this study demonstrates the... The Daily Sign-Out blogs http://www.medworm.com/rss/comments.php?id=4549944 Fri, 04 Mar 2011 21:15:00 +0100 4549944 http://www.medworm.com/index.php?rid=3740847&cid=t_127014_155_f&fid=38412&url=http%3A%2F%2Fpathlabmed.typepad.com%2Fsurgical_pathology_and_la%2F2010%2F07%2Fp53-in-tumorassociated-fibroblasts-in-invasive-ductal-carcinoma.html Hasebe et al. have authored an interesting article in a recent Modern Pathology (2010;23:662-672) which builds on their earlier work that showed P53 expression in tumor-stromal fibroblasts (TSF) not forming fibrotic foci to be an important predictor of outcome in patients with invasive ductal carcinoma.The fibrotic focus has been shown to be a prognostic factor in breast cancer.  Moreover, criteria for fibrotic foci proposed by Van den Eynden et al. in 2007 (Dr. Hasebe was a co-author) appear to both clinically significant and reproducible in daily practice.  I am surprised that the use of this feature has not been adopted for routine use since presenting breast cancer cases with prominent fibrotic foci never fails to elicit curiosity and questions in Tumor Board.  Furthe... The Daily Sign-Out blogs http://www.medworm.com/rss/comments.php?id=3740847 Sat, 10 Jul 2010 03:04:53 +0100 3740847 http://www.medworm.com/index.php?rid=2228345&cid=t_127014_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F03%2F01%2Ffertility-treatments-unlikely-to-raise-ovarian-cancer-risk%2F Ovarian cancer risk was no greater for women who used any of four different groups of fertility drugs [gonadotrophins, clomifenes, human chorionic gonadotrophin, and gonadotrophin releasing hormone] than for those who had not used these drugs. Of the ovarian cancer cases that did occur in this cohort, 58 percent were serous tumors—occurring in the outer [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2228345 Mon, 02 Mar 2009 03:23:06 +0100 2228345 http://www.medworm.com/index.php?rid=2218537&cid=t_127014_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F02%2F25%2Fsometimes-more-is-less-evaluation-of-experimental-platinum-based-treatment-regimens-in-advanced-stage-ovarian-cancer-a-phase-iii-trial-of-the-gynecologic-cancer-intergroup%2F “… Compared with standard paclitaxel and carboplatin, addition of a third cytotoxic agent [gemcitibine, liposomal doxorubicin or topotecan] provided no benefit in PFS [progression-free survival] or OS [overall survival] after optimal or suboptimal cytoreduction. Dual-stage, multiarm, phase III trials can efficiently evaluate multiple experimental regimens against a single reference arm. The development of new interventions [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2218537 Wed, 25 Feb 2009 23:36:44 +0100 2218537 http://www.medworm.com/index.php?rid=692346&cid=t_127014_87_f&fid=34865&url=http%3A%2F%2Fwww.thecancerblog.com%2F2007%2F06%2F23%2Ffemara-and-ovarian-cancer%2F Filed under: Drug, Ovarian Cancer, Clinical Trials, ResearchFemara (letrozole) provides both anticancer responses and disease stabilization in a significant number of patients with recurrent, estrogen receptor positive ovarian cancer. The results of the study were published in Clinical Cancer Research. Femara blocks levels of estrogen in the body, ultimately reducing or preventing growth of estrogen positive cancer cells. Femara has been demonstrated to be effective for estrogen positive breast cancer, but has not yet had a clear influence in women with ovarian cancer. Forty two patients were part of a clinical trial to evaluate the effectiveness of Femara. At three months, 42 percent of patients achieved disease stabilization and 9 percent achieved a regression of their disease. At over s... The Cancer Blog blogs http://www.medworm.com/rss/comments.php?id=692346 Sat, 23 Jun 2007 04:00:00 +0100 692346